Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin versus rosuvastatin + ezetimibe in children with nephrotic syndrome and persistent hyperlipidemia
IRCT20260731070464N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nephrosis comparing Rosuvastatin monotherapy with Rosuvastatin + ezetimibe (2 arms). Primary endpoints: Change in LDL-C level after 6 months, Changes in lipid profile and 1 more. Started Aug 2026; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
nephrosis
Beyond the preview
Go deeper on IRCT20260731070464N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260731070464N1.